ProfileGDS5678 / 1433795_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 86% 92% 92% 91% 89% 93% 95% 94% 93% 89% 93% 93% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9746489
GSM967853U87-EV human glioblastoma xenograft - Control 26.5101286
GSM967854U87-EV human glioblastoma xenograft - Control 37.5738292
GSM967855U87-EV human glioblastoma xenograft - Control 47.7938992
GSM967856U87-EV human glioblastoma xenograft - Control 57.5610291
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.8685789
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.5334993
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.2514595
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.1234194
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8660493
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.0672989
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9639693
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.8464193
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2031990